Gencurix Inc
229000
Company Profile
Business description
Gencurix Inc develops diagnosis treatment kits. The company focuses on developing molecular diagnostic tests based on core technologies of liquid biopsy and biomarker discovery. It offers products including GenesWell BCT, a breast cancer test, GenesWell ddEGFR Mutation Test, Droplex, eDX, Geno CTC, and others.
Contact
243 Digital-ro
15th floor, Jiha City
Guro-gu
Seoul
KORT: +82 7074329481
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
69
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.60 | 48.90 | -0.54% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,839.36 | 205.45 | 0.80% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,699.76 | 55.95 | 0.13% |
| NZX 50 Index | 13,239.63 | 41.51 | -0.31% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,794.40 | 46.50 | -0.53% |
| SSE Composite Index | 3,815.61 | 11.24 | -0.29% |